DDInter777 DDInter1628
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Fosamprenavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fosamprenavir {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fosamprenavir {u} (Compound) resembles {v} (Compound) Darunavir
Darunavir {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fosamprenavir {u} (Compound) resembles {v} (Compound) Darunavir
Darunavir {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fosamprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fosamprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Abiraterone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fosamprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} (Compound) downregulates {v} (Gene) TCERG1
TCERG1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Fosamprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadobenic acid
Gadobenic acid {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fosamprenavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Abiraterone {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Fosamprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rivaroxaban
Rivaroxaban {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fosamprenavir (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Fosamprenavir (Compound) resembles Darunavir (Compound) and Darunavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fosamprenavir (Compound) resembles Darunavir (Compound) and Darunavir (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin (Compound) downregulates TCERG1 (Gene) and TCERG1 (Gene) is upregulated by Ruxolitinib (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid and Gadobenic acid (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Ruxolitinib (Compound)
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)